Cancer drug resistance: an evolving paradigm
The DOI matches its Crossref record; 176 of the 178 references it cites were found in a registry or an index.
Abstract
Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is much value in doing so because the tumor heterogeneity confers unique advantages for the tumor, such as an inherent resistance to therapy [10,11].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [10]
In the citing paper
“This is not surprising, since decades of research on targeted cancer therapy have shown that the majority of patients who respond well to initial treatment develop resistance.57, 58, 59, 60”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, intrinsic and acquired resistance may co-exist and intertwine in the same patient treated with K-RasG12C-targeted therapies.57,61”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“Genomic heterogeneity arising from a variety of co-occurring mutations may contribute to the heterogeneous extent of adaptive resistance across KRAS mutant cancers.57,58”
From Overcoming Resistance to Drugs Targeting KRAS Mutation (2020) · cites this paper as [57]
In the citing paper
“In the clinic, the persister state most closely corresponds to minimal residual disease from which relapse can occur if treatment is discontinued or if acquired drug resistance develops in response to continuous therapy.”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [8]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
5-Fluorouracil: mechanisms of action and clinical strategies
Longley, D. B., Harkin, D. P., & Johnston, P. G. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1074 · Cited by 5,332
Self-citationNew Perspectives in Cell Adhesion: RGD and Integrins
Ruoslahti, E., & Pierschbacher, M. D. (1987) · Science · doi:10.1126/science.2821619 · Cited by 4,865
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Cited by
Items 101–200 of 1,016
The Oral Microbiome and Cancer
Irfan, M., Delgado, R. Z. R., & Frias-Lopez, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.591088 · Cited by 341
Dai, X., Gan, W., Li, X., Wang, S., Zhang, W., Huang, L., Liu, S., Zhong, Q., Guo, J., Zhang, J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4378 · Cited by 330
“Given that resistance to targeted therapies is frequently associated with accumulation of the targeted protein 16–18 , it is crucial to understand how BET protein stability is regulated and whether deregulation of BET protein abundance contributes to cellular resistance to BET inhibitors.”
Zhong, X., He, X., Wang, Y., Hu, Z., Huang, H., Zhao, S., Wei, P., & Li, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01358-5 · Cited by 329
The role of photodynamic therapy in overcoming cancer drug resistance
Spring, B. Q., Rizvi, I., Xu, N., & Hasan, T. (2015) · Photochemical & Photobiological Sciences · doi:10.1039/c4pp00495g · Cited by 335
Cancer therapy in the necroptosis era
Su, Z., Yang, Z., Xie, L., DeWitt, J. P., & Chen, Y. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.8 · Cited by 333
“Drug resistance may result from disrupted apoptosis machinery, overactivated prosurvival signaling pathways, increased expression of the therapeutic target, activation of alternative compensatory pathways, high degree of molecular heterogeneity in tumor cells, upregulation of drug transporters and multidrug resistance…”
BackgroundZhou, P., Li, B., Liu, F., Zhang, M., Wang, Q., Liu, Y., Yao, Y., & Li, D. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0624-9 · Cited by 337
Distinctive properties of metastasis-initiating cells
Celià-Terrassa, T., & Kang, Y. (2016) · Genes & Development · doi:10.1101/gad.277681.116 · Cited by 336
Advances in covalent kinase inhibitors
Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 317
Interaction of tumor-associated macrophages and cancer chemotherapy
Larionova, I., Cherdyntseva, N., Liu, T., Patysheva, M., Rakina, M., & Kzhyshkowska, J. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1596004 · Cited by 322
“acteristics of tumor cells and their sensitivity or resistance to therapeutic agents.(2) On average, only 40–60% of the cancer patients benefit from antitumor chemotherapy (CT).”
BackgroundUnderstanding cancer and the anticancer activities of naphthoquinones – a review
Wellington, K. W. (2015) · RSC Advances · doi:10.1039/c4ra13547d · Cited by 316
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 320
“vasculature regrowth and selection of drug-resistant cell populations during the prolonged drug-free breaks required to recover from host toxicity [53].”
BackgroundMetastasis prevention by targeting the dormant niche
Ghajar, C. M. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3910 · Cited by 320
Carrier-Free, Chemophotodynamic Dual Nanodrugs via Self-Assembly for Synergistic Antitumor Therapy
Zhang, R., Xing, R., Jiao, T., Ma, K., Chen, C., Ma, G., & Yan, X. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b02416 · Cited by 318
Tan, Y., Li, J., Zhao, G., Huang, K.-C., Cardenas, H., Wang, Y., Matei, D., & Cheng, J.-X. (2022) · Nature Communications · doi:10.1038/s41467-022-32101-w · Cited by 306
Drug resistance in cancer: mechanisms and tackling strategies
Haider, T., Pandey, V., Banjare, N., Gupta, P. N., & Soni, V. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00138-7 · Cited by 282
“Platinum drugs MMR and mutation in MMR genes [1]”
BackgroundLow temperature photothermal therapy: Advances and perspectives
Yang, K., Zhao, S., Li, B., Wang, B., Lan, M., & Song, X. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214330 · Cited by 309
The Evolving Landscape of Brain Metastasis
Valiente, M., Ahluwalia, M. S., Boire, A., Brastianos, P. K., Goldberg, S. B., Lee, E. Q., Le Rhun, E., Preusser, M., Winkler, F., & Soffietti, R. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.01.003 · Cited by 309
Insulin-like growth factors: Ligands, binding proteins, and receptors
LeRoith, D., Holly, J. M. P., & Forbes, B. E. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101245 · Cited by 303
“Drug-resistant cancers were associated with upregulation of the IGF-IR, suggesting that cancer used the IGF-IR pathway to escape the effects of therapy and therefore the IGF-IR could be a potential candidate for anti-cancer therapeutic regimes [156,175].”
Raha, D., Wilson, T. R., Peng, J., Peterson, D., Yue, P., Evangelista, M., Wilson, C., Merchant, M., & Settleman, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3456 · Cited by 307
“for CSCs in drug resistance (6) Cancer cells are continuously exposed to extrinsic and intrinsic stresses that promote increased reactive oxygen species (ROS) and DNA damage (7–9).”
BackgroundImmunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y.-X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 308
“Despite initial responses to these conventional therapies, relapse and resistance often occur in patients with advanced cancer after prolonged treatment [5].”
Doxorubicin and other anthracyclines in cancers: Activity, chemoresistance and its overcoming
Mattioli, R., Ilari, A., Colotti, B., Mosca, L., Fazi, F., & Colotti, G. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101205 · Cited by 294
Poised epigenetic states and acquired drug resistance in cancer
Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3819 · Cited by 301
Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
“Mechanisms of acquired resistance to molecular-targeted therapies have been extensively reviewed elsewhere [11, 12].”
Human influences on evolution, and the ecological and societal consequences
Hendry, A. P., Gotanda, K. M., & Svensson, E. I. (2017) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2016.0028 · Cited by 298
Supramolecular “Trojan Horse” for Nuclear Delivery of Dual Anticancer Drugs
Cai, Y., Shen, H., Zhan, J., Lin, M., Dai, L., Ren, C., Shi, Y., Liu, J., Gao, J., & Yang, Z. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b12322 · Cited by 293
Cell-to-cell variation in p53 dynamics leads to fractional killing.
Paek, A. L., Liu, J. C., Loewer, A., Forrester, W. C., & Lahav, G. (2016) · Cell · doi:10.1016/j.cell.2016.03.025 · Cited by 292
“In many cases, resistance has been linked to specific mutations in a subset of tumor cells, allowing them to survive chemotherapy treatment (Holohan et al., 2013).”
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 294
Enzyme‐MOF Nanoreactor Activates Nontoxic Paracetamol for Cancer Therapy
Lian, X., Huang, Y., Zhu, Y., Fang, Y., Zhao, R., Joseph, E., Li, J., Pellois, J., & Zhou, H. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201801378 · Cited by 283
Fisetin and Quercetin: Promising Flavonoids with Chemopreventive Potential
Kashyap, D., Garg, V. K., Tuli, H. S., Yerer, M. B., Sak, K., Sharma, A. K., Kumar, M., Aggarwal, V., & Sandhu, S. S. (2019) · Biomolecules · doi:10.3390/biom9050174 · Cited by 285
Zhong, Y., Zhang, J., Cheng, R., Deng, C., Meng, F., Xie, F., & Zhong, Z. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.01.012 · Cited by 286
“The existence of multidrug resistance (MDR) poses a major obstacle for the clinical treatment of various malignant human cancers [1,2].”
BackgroundCancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes
Ting, N. L.-N., Lau, H. C.-H., & Yu, J. (2022) · Gut · doi:10.1136/gutjnl-2021-326264 · Cited by 274
“78 Since the last decade, the rapid development of immunotherapy has reshaped clinical guidelines in oncology.”
BackgroundPoly (amidoamine) (PAMAM) dendrimer mediated delivery of drug and pDNA/siRNA for cancer therapy
Li, J., Liang, H., Liu, J., & Wang, Z. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.05.045 · Cited by 281
Heat Shock Proteins: Agents of Cancer Development and Therapeutic Targets in Anti-Cancer Therapy
Yun, C. W., Kim, H. J., Lim, J. H., & Lee, S. H. (2019) · Cells · doi:10.3390/cells9010060 · Cited by 284
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
Rudalska, R., Dauch, D., Longerich, T., McJunkin, K., Wuestefeld, T., Kang, T.-W., Hohmeyer, A., Pesic, M., Leibold, J., von Thun, A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3679 · Cited by 282
Yuan, H., Han, Z., Chen, Y., Qi, F., Fang, H., Guo, Z., Zhang, S., & He, W. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202014959 · Cited by 282
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management
Jin, P., Jiang, J., Zhou, L., Huang, Z., Nice, E. C., Huang, C., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01313-4 · Cited by 273
Targeting Notch signalling pathway of cancer stem cells
Venkatesh, V., Nataraj, R., Thangaraj, G. S., Karthikeyan, M., Gnanasekaran, A., Kaginelli, S. B., Kuppanna, G., Kallappa, C. G., & Basalingappa, K. M. (2018) · Stem Cell Investigation · doi:10.21037/sci.2018.02.02 · Cited by 275
“Current cancer treatment has minimum survival rate as these conventional cancer therapies target neoplastic cells that are largely fast-growing in abnormally, suggesting that CSCs may survive due to their high resistance to drugs and slower proliferation rate which leads to treatment failure (2,3).”
BackgroundLoganzo, F., Tan, X., Sung, M., Jin, G., Myers, J. S., Melamud, E., Wang, F., Diesl, V., Follettie, M. T., Musto, S., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0862 · Cited by 278
“Mol Cancer Ther; 14(4) April 2015 Molecular Cancer Therapeutics 958”
BackgroundInfluentialHua, H., Kong, Q., Yin, J., Zhang, J., & Jiang, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00904-3 · Cited by 273
He, C., Liu, D., & Lin, W. (2015) · ACS Nano · doi:10.1021/nn506963h · Cited by 274
“responding to chemotherapeutics after repeated sessions of chemotherapy.(1,2) New”
BackgroundEndoplasmic reticulum stress signaling and chemotherapy resistance in solid cancers
Avril, T., Vauléon, E., & Chevet, E. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.72 · Cited by 277
Mechanism and regulation of pyroptosis-mediated in cancer cell death
Ruan, J., Wang, S., & Wang, J. (2020) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2020.109052 · Cited by 275
The Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272
Therapies targeting cancer stem cells: Current trends and future challenges
Dragu, D. L. (2015) · World Journal of Stem Cells · doi:10.4252/wjsc.v7.i9.1185 · Cited by 257
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 270
“Intrinsic and acquired resistance Drug resistance in cancer can be classified as intrinsic and acquired (including adaptive) [9], for canonical examples refer to [10, 11].”
BackgroundAminoacyl-tRNA synthetases as therapeutic targets
Kwon, N. H., Fox, P. L., & Kim, S. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0026-3 · Cited by 270
Lu, H., Zhang, S., Wu, J., Chen, M., Cai, M.-C., Fu, Y., Li, W., Wang, J., Zhao, X., Yu, Z., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1478 · Cited by 271
“As a result, pharmacologically blocking pro-survival components is considered an effective approach to improve therapeutic index of target-based monotherapy (11-13), whereas cancer-associated defects in apoptosis induction and execution contribute to a significant proportion of treatment failures (14-16).”
BackgroundIshay-Ronen, D., Diepenbruck, M., Kalathur, R. K. R., Sugiyama, N., Tiede, S., Ivanek, R., Bantug, G., Morini, M. F., Wang, J., Hess, C., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.002 · Cited by 270
Liposomes in Cancer Therapy: How Did We Start and Where Are We Now
Fulton, M. D., & Najahi-Missaoui, W. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076615 · Cited by 258
“In addition to surgery, the treatment options usually include a combination of chemotherapy, radiation, and hormonal therapy for advanced stages of cancer [7].”
BackgroundWu, H., Liu, B., Chen, Z., Li, G., & Zhang, Z. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2426-z · Cited by 264
Luo, X., Gong, H.-B., Gao, H.-Y., Wu, Y.-P., Sun, W.-Y., Li, Z.-Q., Wang, G., Liu, B., Liang, L., Kurihara, H., et al. (2021) · Cell Death & Differentiation · doi:10.1038/s41418-020-00719-2 · Cited by 261
“Given the resistance to induce apoptosis in some cancer cells [4], researchers have exploited other”
BackgroundCell of Origin for Malignant Gliomas and Its Implication in Therapeutic Development
Zong, H., Parada, L. F., & Baker, S. J. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020610 · Cited by 269
Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery
Elliott, R. O., & He, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010122 · Cited by 260
Kumar, V., Vashishta, M., Kong, L., Wu, X., Lu, J. J., Guha, C., & Dwarakanath, B. S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.650772 · Cited by 255
Schmitt, H., Billmeier, U., Dieterich, W., Rath, T., Sonnewald, S., Reid, S., Hirschmann, S., Hildner, K., Waldner, M. J., Mudter, J., et al. (2019) · Gut · doi:10.1136/gutjnl-2017-315671 · Cited by 261
New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
Getu, A. A., Tigabu, A., Zhou, M., Lu, J., Fodstad, Ø., & Tan, M. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01751-9 · Cited by 243
“B7-H3 has been linked to treatment resistance also in cancer cells [92, 96].”
BackgroundOxidatively induced DNA damage and its repair in cancer
Dizdaroglu, M. (2015) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2014.11.002 · Cited by 254
Cancer stem cells – important players in tumor therapy resistance
Colak, S., & Medema, J. P. (2014) · The FEBS Journal · doi:10.1111/febs.13023 · Cited by 248
Natural Products for the Management and Prevention of Breast Cancer
Mitra, S., & Dash, R. (2018) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2018/8324696 · Cited by 244
“Chemotherapy is the most popular and most important treatment strategy of cancer; however, there is a rising problem that patient can be unable to respond to chemotherapy due to chemoresistance [249].”
BackgroundCao, T., Zhang, W., Wang, Q., Wang, C., Ma, W., Zhang, C., Ge, M., Tian, M., Yu, J., Jiao, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.011 · Cited by 227
Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms
Hughes, D., & Andersson, D. I. (2015) · Nature Reviews Genetics · doi:10.1038/nrg3922 · Cited by 245
Spring, B. Q., Bryan Sears, R., Zheng, L. Z., Mai, Z., Watanabe, R., Sherwood, M. E., Schoenfeld, D. A., Pogue, B. W., Pereira, S. P., Villa, E., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2015.311 · Cited by 243
SATPdb: a database of structurally annotated therapeutic peptides
Singh, S., Chaudhary, K., Dhanda, S. K., Bhalla, S., Usmani, S. S., Gautam, A., Tuknait, A., Agrawal, P., Mathur, D., & Raghava, G. P. S. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1114 · Cited by 240
“The increasing frequencies of reports of drug resistance are becoming a serious predicament to global healthcare (56).”
Chemoresistance in Pancreatic Cancer Is Driven by Stroma-Derived Insulin-Like Growth Factors
Ireland, L., Santos, A., Ahmed, M. S., Rainer, C., Nielsen, S. R., Quaranta, V., Weyer-Czernilofsky, U., Engle, D. D., Perez-Mancera, P. A., Coupland, S. E., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1201 · Cited by 243
“Drug resistance is one of the biggest challenges in cancer therapeutics and the cause of relapse in the majority of patients with cancer (1, 2).”
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
“As a result of continual treatment, the cancerous cells susceptible to certain drugs become resistant against them, which leads to further complications such as multidrug resistance (MDR), a situation where conventional therapies fail due to the resistance of tumor cells to one or more drugs [4].”
BackgroundTargeting Breast Cancer Metastasis
Jin, X., & Mu, P. (2015) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s25460 · Cited by 233
Deep learning for drug response prediction in cancer
Baptista, D., Ferreira, P. G., & Rocha, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbz171 · Cited by 237
Liu, H., Zhang, W., Zou, B., Wang, J., Deng, Y., & Deng, L. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz1007 · Cited by 230
Mechanisms of Resistance to Antibody–Drug Conjugates
Loganzo, F., Sung, M., & Gerber, H.-P. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0408 · Cited by 231
“This approach has been used to generate resistant tumor models to chemotherapeutic agents commonly used in the clinic (12, 16, 18, 19, 22, 23), and the same approach can be used to induce resistance to ADCs.”
MethodIn Situ Monitoring Apoptosis Process by a Self-Reporting Photosensitizer
Zhang, T., Li, Y., Zheng, Z., Ye, R., Zhang, Y., Kwok, R. T. K., Lam, J. W. Y., & Tang, B. Z. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b00636 · Cited by 235
IL-6 regulates autophagy and chemotherapy resistance by promoting BECN1 phosphorylation
Hu, F., Song, D., Yan, Y., Huang, C., Shen, C., Lan, J., Chen, Y., Liu, A., Wu, Q., Sun, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23923-1 · Cited by 235
Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer
Ji, R., Zhang, B., Zhang, X., Xue, J., Yuan, X., Yan, Y., Wang, M., Zhu, W., Qian, H., & Xu, W. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1005530 · Cited by 233
“MSC-exosomes enhance the anti-apoptotic ability of gastric cancer cells There is accumulating evidence that resistance to apoptosis is a hallmark of cancer and can cause resistance to drug treatment.(18) To further investigate the functional roles of MSC-exosomes in the resistance of gastric cancer cells to chemothera…”
BackgroundHyperthermia and smart drug delivery systems for solid tumor therapy
Seynhaeve, A. L. B., Amin, M., Haemmerich, D., van Rhoon, G. C., & ten Hagen, T. L. M. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.02.004 · Cited by 229
“The capacity of tumor cells to acquire resistance to different chemotherapeutics, (multidrug resistance (MDR)), is a factor that often leads to therapy failure [4,5].”
BackgroundBeretta, G. L., Cassinelli, G., Pennati, M., Zuco, V., & Gatti, L. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.062 · Cited by 235
“, blood brain, blood testis and ovarian-blood folliculate barrier) which limit drug accumulation [8,9], and iii) biochemical, involving several cellular mechanisms including [10,11]: a) mutations of the target; b) oncogene and oncosuppressor gene expression variation; c) activation/improve-”
BackgroundWu, D., Wang, S., Yu, G., & Chen, X. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202010281 · Cited by 228
Du, J., Wan, Z., Wang, C., Lu, F., Wei, M., Wang, D., & Hao, Q. (2021) · Theranostics · doi:10.7150/thno.59121 · Cited by 233
“However, the effectiveness of these therapies in cancer is limited [5, 6].”
BackgroundAn insight on superoxide dismutase (SOD) from plants for mammalian health enhancement
Stephenie, S., Chang, Y. P., Gnanasekaran, A., Esa, N. M., & Gnanaraj, C. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.103917 · Cited by 221
The role of Ubiquitination in Apoptosis and Necroptosis
Roberts, J. Z., Crawford, N., & Longley, D. B. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-021-00922-9 · Cited by 229
“Concluding remark It is evident that ubiquitination plays an important role in regulating both the apoptotic and necroptotic pathways; elucidation of the mechanisms underlying ubiquitin-mediated control of cell death could provide evidence for the development of novel treatments for diseases that have dysregulated cel…”
BackgroundSelf-citationCancer stem cells: A contentious hypothesis now moving forward
O’Connor, M. L., Xiang, D., Shigdar, S., Macdonald, J., Li, Y., Wang, T., Pu, C., Wang, Z., Qiao, L., & Duan, W. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.11.012 · Cited by 233
“Resistance to chemotherapy and molecularly targeted therapies is one of the major causes underlying cancer treatment failure [57].”
BackgroundMeidhof, S., Brabletz, S., Lehmann, W., Preca, B., Mock, K., Ruh, M., Schüler, J., Berthold, M., Weber, A., Burk, U., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404396 · Cited by 229
“There are various molecular mechanisms that lead to treatment resistance, and in a general view, many of those have been linked to a stemness-associated survival phenotype (Holohan et al, 2013).”
BackgroundMouliere, F., El Messaoudi, S., Pang, D., Dritschilo, A., & Thierry, A. R. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.02.005 · Cited by 230
Chemical probes and drug leads from advances in synthetic planning and methodology
Gerry, C. J., & Schreiber, S. L. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.53 · Cited by 230
Chromosomal instability accelerates the evolution of resistance to anti-cancer therapies
Lukow, D. A., Sausville, E. L., Suri, P., Chunduri, N. K., Wieland, A., Leu, J., Smith, J. C., Girish, V., Kumar, A. A., Kendall, J., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.07.009 · Cited by 228
Microfluidic modelling of the tumor microenvironment for anti-cancer drug development
Shang, M., Soon, R. H., Lim, C. T., Khoo, B. L., & Han, J. (2019) · Lab on a Chip · doi:10.1039/c8lc00970h · Cited by 227
Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics
Garcia, S. N., Guedes, R. C., & Marques, M. M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666181213092652 · Cited by 227
Cellular adaptation to cancer therapy along a resistance continuum
França, G. S., Baron, M., King, B. R., Bossowski, J. P., Bjornberg, A., Pour, M., Rao, A., Patel, A. S., Misirlioglu, S., Barkley, D., et al. (2024) · Nature · doi:10.1038/s41586-024-07690-9 · Cited by 207
Simvastatin induced ferroptosis for triple-negative breast cancer therapy
Yao, X., Xie, R., Cao, Y., Tang, J., Men, Y., Peng, H., & Yang, W. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01058-1 · Cited by 227
Zhitomirsky, B., & Assaraf, Y. G. (2015) · Oncotarget · doi:10.18632/oncotarget.2732 · Cited by 225
“However, multidrug resistance (MDR), a phenomenon in which tumor cells display resistance to multiple structurally and functionally unrelated anticancer drugs, is a primary hindrance to curative cancer therapy [1–3].”
BackgroundParadoxical effects of chemotherapy on tumor relapse and metastasis promotion
D’Alterio, C., Scala, S., Sozzi, G., Roz, L., & Bertolini, G. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.019 · Cited by 219
Hiley, C., de Bruin, E. C., McGranahan, N., & Swanton, C. (2014) · Genome Biology · doi:10.1186/s13059-014-0453-8 · Cited by 223
“See [46-52] for more detailed review.”
Postsynthetic Modification of ZIF-90 for Potential Targeted Codelivery of Two Anticancer Drugs
Zhang, F.-M., Dong, H., Zhang, X., Sun, X.-J., Liu, M., Yang, D.-D., Liu, X., & Wei, J.-Z. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b08451 · Cited by 219
Wang, H., Agarwal, P., Zhao, S., Xu, R. X., Yu, J., Lu, X., & He, X. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.08.048 · Cited by 218
“Another approach for overcoming drug resistance is the concurrent use of two or more chemotherapeutic drugs with different anti-tumor mechanisms [19].”
BackgroundCaveolae-Mediated Endocytosis as a Novel Mechanism of Resistance to Trastuzumab Emtansine (T-DM1)
Sung, M., Tan, X., Lu, B., Golas, J., Hosselet, C., Wang, F., Tylaska, L., King, L., Zhou, D., Dushin, R., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0403 · Cited by 215
“The molecular mechanisms that drive clinical drug resistance are multifactorial and ultimately depend upon the therapeutic modality and cancer indication (3).”
BackgroundAdvances in the structure, mechanism and targeting of chemoresistance-linked ABC transporters
Sajid, A., Rahman, H., & Ambudkar, S. V. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00612-3 · Cited by 201
“Thus, the TME could provide refuge for cancer cells from chemotherapeutic drugs and help them to evade apoptosis and develop acquired resistance 256 .”
BackgroundMoS2-based nanocomposites for cancer diagnosis and therapy
Wang, J., Sui, L., Huang, J., Miao, L., Nie, Y., Wang, K., Yang, Z., Huang, Q., Gong, X., Nan, Y., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.04.021 · Cited by 217
“4224 Multidrug resistance (MDR) will reduce the accumulation of drugs in the tumor tissue, reducing the therapeutic effect during cancer chemotherapy [214,215].”
BackgroundYi, H.-C., You, Z.-H., Zhou, X., Cheng, L., Li, X., Jiang, T.-H., & Chen, Z.-H. (2019) · Molecular Therapy - Nucleic Acids · doi:10.1016/j.omtn.2019.04.025 · Cited by 214
“3,4 More obviously, these treatments are expensive and inef fi cient, which means there is an urgent need to develop novel ef fi cient measures to solve this deadly disease.”
BackgroundFeng, W. W., Wilkins, O., Bang, S., Ung, M., Li, J., An, J., del Genio, C., Canfield, K., DiRenzo, J., Wells, W., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.008 · Cited by 216
“Metabolic reprogramming is a fundamental hallmark of cancer (Hanahan and Weinberg, 2011), and it has been reported that adjustments in metabolic preferences can arise as a result of pro-survival mechanisms that allow cancer cells to adapt and proliferate under stressful conditions, such as nutrient deprivation, hypoxi…”
BackgroundMetal-Based Photosensitizers as Inducers of Regulated Cell Death Mechanisms
Zhang, Y., Doan, B.-T., & Gasser, G. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00161 · Cited by 213
De novo and salvage purine synthesis pathways across tissues and tumors
Tran, D. H., Kim, D., Kesavan, R., Brown, H., Dey, T., Soflaee, M. H., Vu, H. S., Tasdogan, A., Guo, J., Bezwada, D., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.011 · Cited by 213
Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities
Antonioli, L., Yegutkin, G. G., Pacher, P., Blandizzi, C., & Haskó, G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.01.003 · Cited by 213
Metadata
- Authors
- Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2013-09-24
- Volume
- 13
- Issue
- 10
- Pages
- 714-726
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2042619042
- Cited by
- 4,681
- References
- 178
- Citations by year
- 2026: 322 · 2025: 358 · 2024: 327 · 2023: 356 · 2022: 364 · 2021: 442 · 2020: 465 · 2019: 460 · 2018: 433 · 2017: 385 · 2016: 342 · 2015: 276 · 2014: 135 · 2013: 4
- FWCI
- 26.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Funders
- Cancer Research UK (13172, 13721, C212/A13721)
- Public Health Agency (RRG/3261/05)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- chemoresistance, targeted therapy, drug target alterations, cell death evasion, predictive biomarkers, patient stratification, high-throughput screening, preclinical models
- MeSH terms
- Adaptation, Physiological, Antineoplastic Agents, Autophagy, Biological Transport, Biotransformation, DNA Damage, DNA Repair, Humans, Models, Biological, Mutation, Neoplasm Proteins, Neoplastic Stem Cells, Drug Design, Gene Expression Regulation, Neoplastic, Apoptosis, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, Gene Silencing, Apoptosis Regulatory Proteins, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.